Earnings
Completion of enrollment of approx. 1000-patient study cohort for Phase 3 RESOLVE-IT study, on the basis of which conditional marketing approval for elafibranor in NASH could be obtained in 2020. Interim data readout expected by end of 2019.
Bluechiip Ltd (ASX:BCT) provides the Company’s Annual Report to shareholders.
MMJ PhytoTech Ltd (ASX:MMJ) (OTCMKTS:MMJJF) provides the Company’s Annual Report to shareholders.
TxCell SA today announces financial results for the first half of 2018 and provides an update on the proposed acquisition by Sangamo Therapeutics, Inc.
Ergomed plc will announce its interim results for the six months ended 30 June 2018 on Wednesday 19th September 2018.
Preliminary anti-tumor activity for lead asset, monalizumab, in combination with cetuximab in advanced head and neck cancer and durvalumab in microsatellite-stable colorectal cancer presented at medical conferences
Vectura regaining momentum with continued inhaled revenue and adjusted EBITDA growth
Positive Topline Results for Diabetic Eye Disease Portfolio
Polyphor AG today announced its financial results for the first half of 2018.
Seventure Partners today announces its corporate update for the period May-August 2018.
PRESS RELEASES